TipRanks on MSN
Sanofi’s Dupixent gains EU approval for chronic urticaria
An update from Sanofi ( ($SNY) ) is now available. On November 25, 2025, Sanofi and Regeneron announced that the European Commission approved ...
Interestingly, despite the autumn’s upward trend, November’s haul is the first in 2025 that doesn’t outweigh the ...
Pharmaceutical Technology on MSN
Dupixent gains chronic spontaneous urticaria indication in Europe
The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decade.
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria ...
Proportion of patients with complete response (UAS7=0).
Paris: Sanofi has announced that the European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in adult and ...
On November 17, 2025 Formycon AG (“Formycon”) announced development of a dupilumab biosimilar, FYB208, referencing Regeneron and Sanofi’s ...
Sanofi is repositioned as a pure pharma play. Following an earnings reset, we see support in ongoing buybacks and higher sales guidance. Q2 results showed strong Dupixent growth, and 2026 readouts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback